FingerMotion, Inc. Common Stock
FNGRFingerMotion, Inc. (FNGR) is a technology company focused on providing mobile content, data analytics, and financial services primarily in China. The company leverages its mobile platform to offer services such as voice, messaging, and data solutions, as well as infrastructure for digital transactions and financial inclusion. FingerMotion aims to connect underserved markets through innovative technology and customized service offerings.
Company News
The most oversold stocks in the communication services sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stoc...
U.S. stocks traded slightly higher, with the Nasdaq Composite gaining around 10 points on Monday. Here are some big stocks recording losses in today’s session. Li-Cycle Holdings Corp. (NYSE: LICY) shares dipped 41% to $1.34 after the company announced plans to halt construction work on its Rochester Hub project, pending completion of a compreh...
U.S. stock futures traded higher this morning on Thursday. Here are some big stocks recording losses in today’s pre-market trading session. Youdao, Inc. (NYSE: DAO) shares tumbled 8.1% to $4.00 in pre-market. E2open Parent Holdings, Inc. (NYSE: ETWO) shares dipped 4.1% to $2.10 in pre-market trading as Redburn Atlantic analyst Alex Haissl down...
U.S. stocks traded higher, with the Nasdaq Composite gaining around 50 points on Friday. Here are some big stocks recording gains in Friday's session. TROOPS, Inc. (NASDAQ: TROO) shares surged 14.9% to $4.4250. NuScale Power Corporation (NYSE: SMR) shares jumped 13.3% to $5.30 after Standard Power chose the company's approved SMR technology and ...
Gainers Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) shares rose 72.4% to $0.2930 in pre-market trading after falling 15% on Tuesday. Brainstorm Cell Therapeutics recently announced the FDA Advisory Committee voted that NurOwn did not demonstrate substantial evidence of effectiveness for treatment of mild to moderate ALS. Sonendo, Inc. (NY...
